安裝中文字典英文字典辭典工具!
安裝中文字典英文字典辭典工具!
|
- 5-Year CROWN Data Show Continued Benefit With Lorlatinib in Advanced . . .
At 5-year follow-up, lorlatinib continues to show progression-free survival (PFS) benefit versus crizotinib in patients with previously untreated advanced ALK-positive non–small cell lung cancer (NSCLC) with no new safety signals Median PFS was not reached with lorlatinib compared with 9 1 months with crizotinib
- If Lorlatinib doesnt work? - 1290044 | CancerGRACE
Stage 4 age 39 March 2011 (very advanced stage 4b) 1) Alimta carbo + radiation 2) Erlotinib 3) Carbo alimta again 5) GK to brain and FOUND ALK 2013 7) Xalkori 6 months 8) Alectinib trial 3 3 years 9) More GK and about to start Lorlatinib Current Issue: We are now about to start Lorlatinib for simultaneous progression to brain and chest
- Lorlatinib or PF-06463922 - 1272666 | CancerGRACE
I am nearly 5 years living with ALK+ stage IV disease Brain mets occurred in 5 2014 - asymptomatic Decreased with switch to ceretinib 2 15 brain mets grew - treated with SRS 10 1 - more brain mets with symptoms, treated with RT to cerebellum 12 1- Started on lorlatinib (PF-06463922)
- ASCO 2017 - Lung Cancer - Sequencing Treatments for ALK+ Lung Cancer in . . .
Drs H Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer In this video, the doctors discuss Sequencing Treatments for ALK+ Lung Cancer in a Crowded Field - Is there a place for Lorlatinib?
- ALK+ next treatment option | CancerGRACE
- Presently on Lorlatinib:: From Jan 2022 onwards (she has been on Lorlatinib for around 20 months on a reduced dosage of 50mg every alternate, due to toxicity) Her most recent PET scan from 10 20 23 reveals a stable situation with minimal Loculated Pleural effusion (around 75 – 100ml)
- 2022 Targeted Therapies Patient Forum Advances ALK+, RET+, and MET+ NSCLC
we have introduced Lorlatinib as a first-line alternative in this particular subgroup I just want to show you one outcome study This study is from the University of Colorado where I was working before This is a group of patients with advanced disease Remember, 1015 years ago, the -
- lorlatinib | CancerGRACE
Enter your Keywords Menu
- Unlocking Precision in Lung Cancer: Understanding and Overcoming . . .
Next-Generation ALK Inhibitors: Newer ALK inhibitors, such as lorlatinib and repotrectinib, have been developed to target resistant ALK mutations Combination Therapies: Combining ALK inhibitors with agents targeting bypass signaling pathways or EMT can overcome resistance
|
|
|